Graseck, Anna S. MD, MSCI; Secura, Gina M. PhD, MPH; Allsworth, Jenifer E. PhD; Madden, Tessa MD, MPH; Peipert, Jeffrey F. MD, PhD
An estimated 19 million new sexually transmitted infections occur each year in the United States, making sexually transmitted infections a major public health problem.1 Because half of cases occur in young adults, the Centers for Disease Control and Prevention currently recommends that girls and women age 25 years and younger receive annual sexually transmitted infection screening.1,2 However, only 26–60% of at-risk women in the United States do so.3–6
Barriers to clinic access can be reduced with the use of self-obtained vaginal swabs in home-based screening. Noninvasive sexually transmitted infection screening has been well accepted by women in a variety of nonclinical settings.7–11 In a prospective cohort study, we found that women preferred home-based screening, and those who chose it were more likely to complete screening.12 Two randomized trials in Denmark13,14 and one in the United States,15 which studied high-risk adolescents, have also shown improved screening rates with home tests.
We conducted a trial that randomized women using long-acting reversible contraception to home or clinic-based sexually transmitted infection screening. Long-acting reversible contraception, which includes intrauterine devices and subdermal implants, was used by 66% of the population in our previous study.12 The National Survey of Family Growth reported that intrauterine device use increased from 2% to 2002 to 5.5% in 2006–2008.16 Because these contraceptive methods are effective for 3–10 years, long-acting reversible contraception users may not seek medical care on an annual basis, making sexually transmitted infection screening through self-collection a potentially desirable option. We sought to estimate which screening method would produce the highest sexually transmitted infection screening rate among long-acting reversible contraception users.
MATERIALS AND METHODS
The Contraceptive CHOICE Project is a prospective cohort study seeking to recruit 10,000 women and to promote the use of long-acting reversible contraception.17 Participants are recruited from a university-based clinic, two abortion clinics, and several community-based clinics. Women are eligible for the study if they are between the ages of 14 and 45 years, speak English or Spanish, are seeking a new method of reversible contraception or are not currently using a method, have not had a hysterectomy or tubal sterilization, and are currently sexually active with a male partner or planning to become sexually active in the next 6 months. Informed consent is obtained for all participants. We obtained approval from the Washington University School of Medicine Human Research Protection Office before starting recruitment. After receiving comprehensive counseling on contraceptive options, participants choose a reversible contraceptive method that is provided at no cost for the 3-year study period. Telephone follow-up occurs at 3 months, 6 months, and every 6 months thereafter for the duration of the study for a total of seven contacts.
All women enrolled in the study are offered sexually transmitted infection screening at baseline then again at 12, 24, and 36 months postenrollment. At baseline, all women are instructed on the proper technique to self-collect a vaginal swab. Swabs were tested for Chlamydia trachomatis and Neisseria gonorrhoeae using the BDProbeTec ET instrument through DNA strand displacement amplification technology. These specimens can be stored at room temperature and must be received by the testing laboratory within 16 days of collection.
This substudy randomized 558 women to home- or clinic-based screening for the 12-month scheduled sexually transmitted infection screen. Women were randomized using computer-based randomization if they completed the baseline survey and consented to the substudy at enrollment. For each participant, a random number was generated using the uniform distribution with a cut point of 0.50. Those below this cut point were assigned to one treatment and above to the control. Staff and participants were blinded to the randomization status until the time of testing (12 months), and randomization was performed by an author who did not have contact with study participants. At the 12-month survey, participants were required to be living in the United States and using a long-acting reversible method of contraception defined as the levonorgestrel intrauterine system, Copper T 380A intrauterine device, or the contraceptive subdermal implant. Participants identified as eligible by these criteria were given instructions to screen for sexually transmitted infections by randomization group. Participants could refuse testing for any reason. Recruitment ended August 1, 2009, after the desired sample size was reached.
Participants randomized to the home-based screening group were mailed a collection kit. The kits were packaged in a plain brown box and could be sent to any address the woman provided (eg, a friend's house) to address potential privacy concerns. A vaginal swab and collection tube were provided, identical to those used at baseline screening. Detailed, step-by-step instructions with photographs explained how to collect the specimen and return it in a prepaid, preaddressed mailer, which complied with Department of Transportation and U.S. Postal Service regulations.
Women randomized to clinic-based screening were able to test with their regular healthcare provider or at four local family planning clinics. Women in the clinic arm were mailed written instructions, which stated that participants could be reimbursed for any expenses of sexually transmitted infection testing and treatment, and asked participants to provide medical records of such testing. Medical records release forms for the participant's primary healthcare provider were signed at enrollment. However, if the participant planned to test with a different healthcare provider, a new release form was mailed to the participant with a postage-paid return envelope.
As another clinic-based option, all women in the clinic-based randomization group were given written instructions to obtain testing at one of four family planning clinics. This was designed to accommodate participants without access to a private healthcare provider, although all participants were able to test at these clinics. No appointment was necessary and there was no cost for screening. The clinics were provided with self-collected vaginal swab kits as used in the home-based group.
Specimens from home kits were received by mail daily, and specimens from family planning clinics were returned within 5 days of specimen collection. Specimens that were not in satisfactory condition for testing (eg, missing swab or low preservative fluid) were rejected, and the participant was asked to come to the study clinic to collect a new sample. Women with positive tests for C. trachomatis or N. gonorrhoeae were contacted by a research nurse and provided with antibiotic treatment for herself and all partners at no cost to the participant.
Medical records were requested for all participants in the clinic-based group who had not documented screening by providing medical records or a specimen from the family planning clinics. A records request was sent to the healthcare provider with whom the participant had intended to test. If a valid release for this healthcare provider was not available, a release was sent to the participant to sign and return, and requests were sent to any other healthcare provider for whom we had a valid medical records release. Two attempts were made to contact each healthcare provider. We did not request records from the family planning clinics where self-collected screening was available if participants listed this facility as their healthcare provider. Participants who presented there could receive testing through our study at no cost and without an appointment and were thus unlikely to have been tested by other means at these sites.
Baseline and 12-month follow-up interviews collected detailed information on demographic characteristics, contraceptive use, reproductive history, sexually transmitted infection diagnosis and treatment, and sexual behavior with male and female partners. Women were mailed a written survey addressing satisfaction with the sexually transmitted infection screening process 56 days after testing was offered. A postage-paid return envelope was provided. At the 18-month telephone interview, the next regularly scheduled follow-up after randomized sexually transmitted infection screening, women were asked if they had undergone sexually transmitted infection screening. If they had not screened, they were asked to provide one or more reasons why not.
The testing period was defined as 56 days after the 12-month interview date (coinciding with mailing of the satisfaction survey) so that the mailed survey did not serve as a reminder to complete screening. A completed test was defined as a received sample from the home kit or family planning clinic during the testing period; medical record documentation of a test for C. trachomatis and N. gonorrhoeae during the testing period; or self-report of screening on the mailed survey or 18-month telephone survey. A second outcome variable, documented completed tests, considered a participant “not screened” if no medical record documentation could be found confirming her self-report of screening during the testing period.
Baseline characteristics of the home and clinic-based testing groups, and screening completers compared with noncompleters, were compared using χ2 for categorical variables and Student's t test for continuous variables. Ordinal data in the satisfaction survey were analyzed by the Mann-Whitney U test. The hypothesis that the home-based screening group would have a higher proportion of completed tests was tested using the χ2 test and quantified with a simple relative risk (RR) calculation. When the outcome of interest (completed tests) is common (more than 10%) in prospective studies, logistic regression may produce a biased estimate of the RR with the extent of the bias related to the prevalence of the outcome.18 To correct for this bias, we performed a Poisson regression with robust error variance; this method is one methodologic approach that produces an unbiased estimate of both the RR and 95% confidence intervals (CIs).19,20 SPSS 17 and SAS 9.2 were used for statistical analyses. Based on a testing percentage of 35% in the clinic-based group, a 15% difference in testing rates between groups (testing in the home group of 50%), and α of 0.05, we needed 242 patients per group (total n=484) to achieve 90% power.
A total of 561 women were eligible for the study (Fig. 1). At the 12-month interview, three women living outside of the United States were excluded. Ten women (2%) refused sexually transmitted infection screening, five women from each randomization group. Five (50%) women refused screening because they considered themselves at low risk, four (40%) because they had recently been tested, and one (10%) woman was not interested in sexually transmitted infection screening. There were no differences in refusal reason by randomization group. Of the 548 women intending to screen, 268 were randomized to home-based screening and 280 were randomized to clinic-based screening. Seven women were not offered testing according to their randomization status; two were randomized to home-based screening but offered clinic-based screening, and five in the clinic group were offered home-based screening. These participants were analyzed in the group to which they were randomized. The randomization groups had a different distribution of marital status; the clinic group had more never-married women (62.0% compared with 51.6%); and the home group had more separated, divorced, or widowed women (12.1% compared with 5.6%, P=.007). There were no other differences between the randomization groups at baseline in demographic characteristics, sexual behavior, or access to health care (Table 1).
Overall, 243 (44.3%) of women completed screening. Of 202 specimens received for processing by the study, three were rejected for quality: two had low liquid and one had no swab. Three additional tests appeared in good condition but were considered unsatisfactory by the laboratory. All women with unsatisfactory results were given the opportunity to retest at the study clinic; two women did and tested negative.
Women randomized to home-based screening were almost 70% more likely to complete a screen compared with women randomized to clinic-based screening (56.3% compared with 32.9%; RR 1.7; 95% CI 1.4–2.1). Completion status did not differ by age, race, access to health care, or history of a prior sexually transmitted infection. However, completers were more likely to have higher educational attainment (P=.005). Completers were also more likely to be welfare recipients (P=.009; RR 1.04; 95% CI 1.01–1.07; Table 2), but there was no difference by any other form of government assistance (Women, Infants, and Children; food stamps). Using Poisson regression with robust error variance to adjust for age, race, education, marital status, and welfare use, nearly identical results were obtained (RR 1.7; 95% CI 1.4–2.0). Seven cases of Chlamydia were detected, three in the home group and four in the clinic group. One case of gonorrhea was detected in the clinic group.
Medical records or a specimen were obtained for 163 (58%) of women in the clinic randomization group. We did not receive specimens from the family planning clinic for 65 women who we assumed were not tested elsewhere. Of these, 42 (15%) listed this clinic as their primary healthcare provider, and 23 (8%) did not have access to a primary healthcare provider and planned to go to the family planning clinic. For the remaining 52 women for whom we could not obtain medical records, 26 (9%) did not have a valid medical records release for any healthcare provider, 10 (4%) healthcare providers did not respond, eight (3%) healthcare providers could not be contacted, seven (2%) healthcare providers refused our request, and one woman was given a home kit, which was not returned. Of the 94 medical records received, six documented a test during the testing period, 13 documented a recent test that was outside of the testing period, and 75 did not record any recent sexually transmitted infection tests. Using these documented completed screens, women in the home group were more than twice as likely to complete a test (56.3% compared with 25.0%; RR 2.3; 95% CI 1.8–2.8). Poisson regression with robust error variance adjusting for age, race, education, marital status, and welfare use produced similar results (RR 2.2; 95% CI 1.7–2.7).
At the next regularly scheduled follow-up (18 months), 207 women who did not complete testing gave reasons for not screening. The most common reason was forgetting to test, reported by 67 (32%) noncompleters. Other common reasons included lack of time (n=34 [16%]), not receiving testing materials (n=31 [15%]), testing outside of the study (n=25 [12%]), and losing or damaging testing materials (n=23 [11%]). When analyzed by randomization group, noncompleters in the home arm were more likely to have forgotten or not understood how to use the self-swab and less likely to cite lack of time (Table 3). Financial or transportation concerns, and other clinic barriers such as appointment availability, were more common in the clinic group but did not reach statistical significance.
Twenty-three percent of women returned the mailed satisfaction survey (n=122), and response rates did not differ by randomization group (P=.49). The majority of respondents (n=98 [81%]) were very or somewhat satisfied with the testing process and were not concerned about privacy (n=92 [95%]). All women who used the self-swab thought it was easy to use with 70% (n=53) considering the collection step “extremely easy.” By the Mann-Whitney U test, women in the home group gave higher ratings for convenience (somewhat or very convenient, 89% in the home group compared with 69% in the clinic group, P=.02). Women randomized to home strongly preferred to test at home again (83%) compared with only 49% of women in the clinic group who would choose clinic-based testing in the future (Mann-Whitney U, P<.001).
This randomized trial of home- compared with clinic-based screening for Chlamydia and gonorrhea demonstrated increased screening rates in women randomized to home-based screening. Home-based screening nearly doubled screening rates compared with clinic-based screening in both univariate and multivariate analysis. Several cases of Chlamydia and one case of gonorrhea were detected in both screening arms.
Home-based screening is a viable alternative to clinic-based screening as a result of the availability of nucleic acid amplification tests such as polymerase chain reaction, strand displacement analysis, and transcription-mediated amplification. These methods have high sensitivity and specificity for detection of both C. trachomatis and N. gonorrhoeae. Self-obtained vaginal swabs produce results that are nearly identical to clinically obtained endocervical samples.3,21
Several studies have demonstrated that women consider self-collected vaginal swabs an acceptable alternative to traditional screening by a clinician.22,23 Our previous cohort study demonstrated that women strongly preferred home screening with 75% of the sample choosing it rather than clinic-based screening.12 Respondents to a mailed satisfaction survey also showed a preference for home-based screening. Most women in the home group would choose to use home-based screening again, whereas half of the women in the clinic group preferred to switch methods and use home screening in the future.
One strength of this study is its randomized design, which achieved a balanced distribution of clinical and demographic factors. Because assignment of screening method was randomized in this study, we are confident that the improvement in screening rates is the result of the screening method itself rather than characteristics of women choosing home screening. Another strength is the diverse population of contraceptive-seeking women recruited by the Contraceptive CHOICE Project, which has a broad distribution of socioeconomic and sexually transmitted infection risk factors. Similar to our previous study, we demonstrated a low rate of unsatisfactory results (3%) among the women using self-obtained vaginal swabs.12 One hundred percent of women responding to the mailed survey considered the swabs “easy” or “extremely easy” to obtain. These results support our conclusion that women can properly obtain and ship vaginal swabs for testing.
We used two different methods to determine the primary outcome measure, the number of completed tests. Although all self-obtained vaginal swabs could be accurately counted as they were processed at the study site, women in the clinic group may not have reported being tested with a private healthcare provider. To reduce bias, we used several methods to determine the screening status for all women in the clinic group, including review of reimbursement forms, self-report by mailed and telephone surveys, and systematic attempts to retrieve outside medical records. Using these strategies, we can estimate that the true screening rate in the clinic testing arm was between the rate of 24% confirmed by records and 32% with the addition of self-report. The rate confirmed by records is a conservative estimate, because we were unable to obtain records for all women, and some women may have tested with a different healthcare provider than that listed in her study records. However, self-report is also biased as a result of poor recall, response bias and the common misconception that sexually transmitted infection screening is performed during all pelvic examinations.
This study was limited to women using long-acting methods of contraception. Future research could address whether these conclusions are altered in populations using different contraceptive methods. However, our previous study showed that contraceptive method did not influence completion rates. Use of long-acting reversible contraception is increasing and is likely to continue to rise as patient and healthcare provider awareness increase.16 Home-based testing is a promising strategy to screen women such as women using long-acting reversible contraception who may not present for annual gynecologic examinations.
All women, regardless of their choice of contraception, can benefit from improved access to sexually transmitted infection screening. Women in the clinic group who did not complete testing were more likely to cite time constraints as a barrier to testing compared with the home group. Although lack of transportation and other clinic-based barriers were cited by few women, these barriers are eliminated by home-based testing. U.S. Food and Drug Administration approval of an over-the-counter Chlamydia and gonorrhea testing kit and access to affordable home-based testing options would allow private and convenient self-testing to be available outside of the research setting. Screening must be easily available, affordable, and convenient to meet Centers for Disease Control and Prevention recommendations. Furthermore, the availability of sexually transmitted infection screening options outside of the traditional clinic setting for women who may not require or seek annual gynecologic care are necessary if we hope to reduce sexually transmitted infections among women.
1. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6–10.
2. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55(RR-11):1–94.
3. Cook RL, Hutchison SL, Østergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive testing for Chlamydia trachomatis
and Neisseria gonorrhoeae
. Ann Intern Med 2005;142:914–25.
4. Levine WC, Dicker LW, Devine O, Mosure DJ. Indirect estimation of Chlamydia screening coverage using public health surveillance data. Am J Epidemiol 2004;160:91–6.
5. St Lawrence JS, Montano DE, Kasprzyk D, Phillips WR, Armstrong K, Leichliter JS. STD screening, testing, case reporting, and clinical and partner notification practices: a national survey of US physicians. Am J Public Health 2002;92:1784–8.
6. Chlamydia screening among sexually active young female enrollees of health plans—United States, 1999–2001. MMWR Morb Mortal Wkly Rep 2004;53:983–5.
7. Bauer HM, Chartier M, Kessell E, Packel L, Brammeier M, Little M, et al. Chlamydia screening of youth and young adults in non-clinical settings throughout California. Sex Transm Dis 2004;31:409–14.
8. Bloomfield PJ, Kent C, Campbell D, Hanbrook L, Klausner JD. Community-based chlamydia and gonorrhea screening through the United States mail, San Francisco. Sex Transm Dis 2002;29:294–7.
9. Gaydos CA, Dwyer K, Barnes M, Rizzo-Price PA, Wood BJ, Flemming T, et al. Internet-based screening for Chlamydia trachomatis
to reach non-clinic populations with mailed self-administered vaginal swabs. Sex Transm Dis 2006;33:451–7.
10. Macleod J, Salisbury C, Low N, McCarthy A, Sterne JA, Holloway A, et al. Coverage and uptake of systematic postal screening for genital Chlamydia trachomatis
and prevalence of infection in the United Kingdom general population: cross sectional study. BMJ 2005;330:940.
11. Novak DP, Karlsson RB. Simplifying chlamydia testing: an innovative Chlamydia trachomatis
testing approach using the internet and a home sampling strategy: population based study. Sex Transm Infect 2006;82:142–7; discussion 152–3.
12. Graseck AS, Secura GM, Allsworth JE, Madden T, Peipert JF. Home screening compared with clinic-based screening for sexually transmitted infections. Obstet Gynecol 2010;115:745–52.
13. Ostergaard L, Andersen B, Møller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis
in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 2000;31:951–7.
14. Ostergaard L, Andersen B, Olesen F, Moller JK. Efficacy of home sampling for screening of Chlamydia trachomatis
: randomised study. BMJ 1998;317:26–7.
15. Cook RL, Østergaard L, Hillier SL, Murray PJ, Chang CC, Comer DM, et al. Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trial. Sex Transm Infect 2007;83:286–91.
16. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 2010;23 (29).
17. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol 2010;203:115.e1–7.
18. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690–1.
19. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940–3.
20. Robbins AS, Chao SY, Fonseca VP. What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes. Ann Epidemiol 2002;12:452–4.
21. Hobbs MM, van der Pol B, Totten P, Gaydos CA, Wald A, Warren T, et al. From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis 2008;35:8–13.
22. Wiesenfeld HC, Lowry DL, Heine RP, Krohn MA, Bittner H, Kellinger K, et al. Self-collection of vaginal swabs for the detection of Chlamydia, gonorrhea, and trichomoniasis: opportunity to encourage sexually transmitted disease testing among adolescents. Sex Transm Dis 2001;28:321–5.
23. Chernesky MA, Hook EW 3rd, Martin DH, Lane J, Johnson R, Jordan JA, et al. Women find it easy and prefer to collect their own vaginal swabs to diagnose Chlamydia trachomatis
or Neisseria gonorrhoeae
infections. Sex Transm Dis 2005;32:729–33.
© 2010 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.